GlassScriptPhysician profile
Mary Mock
NPI 1760168454
$1,178.41
in general payments reported to CMS, 2019-2025
19 companies · $856 in 2025
The $856 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.30 · 2024: $309 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $195.91 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $187.23 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.67 | 2024-2025 | Caplyta |
| Lundbeck LLC | $149.56 | 2025 | Rexulti, Vyepti |
| Astrazeneca Pharmaceuticals LP | $93.35 | 2024-2025 | Farxiga, Airsupra |
| Pfizer INC. | $64.08 | 2024 | |
| Novo Nordisk INC | $52.83 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Paratek Pharmaceuticals, INC. | $52.01 | 2025 | Nuzyra |
| Viatris Specialty LLC | $39.79 | 2025 | Yupelri |
| Lilly USA, LLC | $38.13 | 2025 | Kisunla |
| Otsuka America Pharmaceutical, INC. | $28.21 | 2025 | Rexulti |
| Mannkind Corporation | $19.61 | 2025 | |
| Dexcom, INC. | $19.21 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $17.27 | 2025 | Keveyis |
| Medtronic, INC. | $16.39 | 2025 | Inceptiv |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $13.47 | 2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $13.40 | 2024 | Contrave |
| Phathom Pharmaceuticals, INC. | $12.81 | 2025 | Voquezna |
| Echosens North America, INC. | $10.48 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.